Halozyme to Restructure After Pancreatic Cancer Drug Fails in Phase 3; 55% of Workforce to be Cut

An experimental Halozyme Therapeutics treatment for pancreatic cancer has failed a pivotal study, and the company is stopping further development of the drug and closing its oncology operations as part of a corporate restructuring.